A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women

Benster, Beverly; Carey, Adam; Wadsworth, Fred; Vashisht, Arvind; Domoney, Claudine; Studd, John

doi:10.1258/mi.2009.009014

Cited by 32 publications

(33 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was also a small trend favoring progesterone over MPA with regards to beliefs of effectiveness (menopause related vasomotor symptoms and improving quality of life) and safety (Table 5). Again, these beliefs reflect some of the data reported in the literature, however at this time the evidence is equivocal 19,20,27,51,52,53,54…”

Section: Discussionsupporting

confidence: 75%

Bioidentical hormone therapy: Nova Scotia pharmacists´ knowledge and beliefs

Whelan

Thebeau

Jurgens

et al. 2012

Pharmacy Practice (Internet)

View full text Add to dashboard Cite

ObjectiveTo investigate Nova Scotia (NS) pharmacists' knowledge and beliefs regarding the use of bioidentical hormones (BHs) for the management of menopause related symptoms.MethodsUsing Dillman’s tailored design methodology, an invitation to complete the web-based questionnaire was emailed to pharmacists in NS as part of the Dalhousie College of Pharmacy Continuing Pharmacy Education Department's (CPE) weekly email update. Data was analyzed using descriptive statistics.ResultsOf approximately 1300 e-mails sent, 113 pharmacists completed the questionnaire (response rate 8.7%). The majority of respondents (94%) knew that BHs were not free from adverse drug reactions. More than 50% were aware that conjugated equine estrogens and medroxyprogesterone acetate were not examples of BHs. For seven of eleven knowledge questions, 33-45% indicated that they did not know the answer. When asked about their beliefs regarding BHs, many believed that BHs were similar in efficacy (49%) or more effective (21%) than conventional hormone therapy (CHT) for vasomotor symptoms. Most respondents also believed that both BHs and CHT had similar safety profiles. Additionally, responding pharmacists indicated that more education would be helpful, especially in the area of safety and efficacy of BHTs compared to CHT.ConclusionsNS pharmacists knew BHs were not free of adverse effects, however knowledge was lacking in other areas. This may reflect the level of coverage of this topic in pharmacy school curriculums and in the pharmacy literature. Results indicate a need for additional education of NS pharmacists with respect to BHs, which could be accomplished through modification of undergraduate pharmacy programs and supplementary CPE.

show abstract

Section: Discussionsupporting

confidence: 75%

Bioidentical hormone therapy: Nova Scotia pharmacists´ knowledge and beliefs

Whelan

Thebeau

Jurgens

et al. 2012

Pharmacy Practice (Internet)

View full text Add to dashboard Cite

show abstract

“…There was a nearly significant difference in the decrease in VMS by assignment (p ¼ 0.07) but a non-significant difference by MENQOL 49 . The third RCT of tP4 was a five-arm, double-blind, dose-ranging trial of placebo to 5, 20, 40 and 60 mg/day; 223 women were enrolled and were analyzed by intentto-treat 51 . It was a well-conducted study with a consort A fourth cross-over, 1-month RCT of tP4 in 30 symptomatic menopausal women did not detail VMS changes separately from the total changes in Greene Climacteric Scale and was focused on inflammatory and thrombotic markers 52 .…”

Section: Transdermal (Cream) Progesteronementioning

confidence: 99%

Progesterone for treatment of symptomatic menopausal women

Prior

2018

Climacteric

View full text Add to dashboard Cite

This review's purpose is to highlight evidence that oral micronized progesterone (progesterone) is effective for hot flushes and night sweats (vasomotor symptoms, VMS), improves sleep and is likely safe in menopausal women (who are more than 1 year since last menstruation). Methods include randomized controlled clinical trials (RCT) supplemented with basic science, population and observational data as needed. The barrier to use of progesterone is lack of awareness that safety concerns with estrogenincluding 'menopausal hormone therapy' (MHT) are not applicable to progesterone. In a single 3-month RCT, progesterone (300 mg at bedtime) was effective treatment of VMS in 133 healthy menopausal women. It caused an overall 55% VMS decrease, no withdrawal-related VMS rebound and a greater VMS decrease in 46 women with !50 moderate-intense VMS/week. Progesterone is equally or more effective than estradiol in improving cardiovascular endothelial function and caused no cardiovascular safety concerns in a 3-month RCT. An 8-year prospective cohort study (E3N) in more than 80 000 menopausal women showed progesterone prevented breast cancer in estrogen-treated women. Multiple RCTs confirm that progesterone (300 mg daily at bedtime) does not cause depression and improves deep sleep. In conclusion, progesterone effectively treats VMS, improves sleep and may be the only therapy that symptomatic women, who are menopausal at a normal age and without osteoporosis, need. ARTICLE HISTORY

show abstract

“…While the use of oral and i.m. progestational agents has demonstrated significant efficacy in randomized trials, the role of progesterone cream for alleviating hot flashes remains a controversial topic, because placebo-controlled, randomized trials involving these agents have provided conflicting evidence [35,36]. Furthermore, although oral and i.m.…”

Section: Progestational Agentsmentioning

confidence: 99%